Download the app
App StorePlay Store
Beige
Login
← All tags

pharma

Sun Pharma Torrent Alkem face scrutiny over inferior medicines and a leaky supply chain

Sun Pharma Torrent Alkem face scrutiny over inferior medicines and a leaky supply chain

India’s drug trust crisis is widening as Sun Pharma, Torrent, and Alkem come under scrutiny for alleged “not of standard quality” medicines. Government agencies recently pulled up more than 50 popular brands, raising fears that the supply chain may be allowing inferior drugs to slip through. The big question now is how patients can reliably trust what they take.

Summarised by Beize from a story on The Economic Times on 24 Apr 2026
NMDC and Suzlon swing the market as post earnings rallies collide with profit booking

NMDC and Suzlon swing the market as post earnings rallies collide with profit booking

Indian indices closed higher as auto, pharma and metal stocks lifted sentiment. NMDC, Apollo Hospitals, Nykaa and BDL surged after earnings, while Suzlon, RVNL and Waaree Energies declined on weaker results and profit booking. The day’s sharp moves highlight how quickly investor expectations can flip between buyers and sellers.

Summarised by Beize from a story on The Economic Times on 24 Apr 2026

Your news, in seconds

App StorePlay Store
From facilitator to regulator Rajeev Raghuvanshi tackles pharma quality crisis after Gambia deaths

From facilitator to regulator Rajeev Raghuvanshi tackles pharma quality crisis after Gambia deaths

After 70 children died in Gambia in 2022 linked to contaminated cough syrups, India’s pharma sector and its top regulator faced a credibility crisis. Rajeev Raghuvanshi, appointed Drug Controller General of India, is now pushing a transformation aimed at closing regulatory gaps and tightening product quality. The big question: can enforcement finally keep pace?

Summarised by Beize from a story on The Economic Times on 24 Apr 2026
Indian pharma giant joins the weight loss race with a new obesity drug find

Indian pharma giant joins the weight loss race with a new obesity drug find

Weight-loss drugs have become a high-stakes global opportunity, and now a major Indian pharma player is stepping into the obesity fight with a fresh drug development. The move signals intensifying competition as companies chase demand for effective treatments, where speed to scale, manufacturing reach, and clinical promise could decide who leads the next wave of obesity medicines worldwide.

Summarised by Beize from a story on The Economic Times on 24 Apr 2026
Glenmark Ichnos drug shows promise against multiple myeloma but can it beat Big Pharma

Glenmark Ichnos drug shows promise against multiple myeloma but can it beat Big Pharma

Glenmark’s Ichnos drug is showing promising results for multiple myeloma, a rare blood cancer, raising hopes for affordable breakthrough therapy. With the global market for such drugs projected to reach about USD 30 billion by decade’s end, the question is whether early clinical signals can translate into scale and pricing power against global heavyweights like J&J, Gilead, and Sanofi.

Summarised by Beize from a story on The Economic Times on 24 Apr 2026
Healthcare and pharma jobs to surge by 2030 as tech reshapes hiring

Healthcare and pharma jobs to surge by 2030 as tech reshapes hiring

A new Adecco India report says India’s healthcare and pharmaceutical sector is shifting into capability-led growth, with job creation projected to reach 2–2.5 million by 2030. Hiring is moving toward specialised roles and deeper technology integration across hospitals, telemedicine, diagnostics, clinical research, AYUSH, and elder and home care.

Summarised by Beize from a story on The Economic Times on 24 Apr 2026

Never miss a story

App StorePlay Store
Bayer to push harder on tiered pricing for its drugs in India

Bayer to push harder on tiered pricing for its drugs in India

In an exclusive interview, Bayer’s global head of pharmaceuticals, Stefan Oelrich, said the company will intensify its push for tiered pricing in India. The move is linked to Bayer’s “tailormade India” portfolio and its broader investment plans in innovation, aiming to balance affordability with business sustainability.

Summarised by Beize from a story on The Economic Times on 24 Apr 2026
Bombay High Court bars Meghmani Lifesciences from using Esiraft over confusion with Sun Pharma

Bombay High Court bars Meghmani Lifesciences from using Esiraft over confusion with Sun Pharma

Sun Pharmaceutical has won a trademark dispute in Bombay High Court, which barred Meghmani Lifesciences from using the drug mark “Esiraft.” The court accepted Sun’s claim that Meghmani’s “Esiraft” is visually and phonetically similar to Sun’s “Raciraft,” creating a strong likelihood of consumer confusion and amounting to infringement and passing off.

Summarised by Beize from a story on The Economic Times on 24 Apr 2026
Fake drugs and Jan Aushadhi pressure pharma profits and shake market confidence

Fake drugs and Jan Aushadhi pressure pharma profits and shake market confidence

India’s pharma market, valued around INR 2.17 lakh crore, faces mounting profit pressure as fake drugs erode trust and government Jan Aushadhi initiatives intensify competition. Industry voices point to early signs of fatigue, but many insist the sector isn’t collapsing and a rebound could still be on the horizon if enforcement and demand dynamics improve.

Summarised by Beize from a story on The Economic Times on 24 Apr 2026
AstraZeneca India eyes Rs 3400 crore sale of 64 acre Bengaluru land as developers circle

AstraZeneca India eyes Rs 3400 crore sale of 64 acre Bengaluru land as developers circle

AstraZeneca Pharma India is planning to sell a 64-acre site in Bengaluru, targeting about ₹3,400 crore as part of its land monetisation strategy. The parcel has attracted interest from developers including the Sattva Group, Aurobindo Pharma and RMZ, with negotiations expected to shape how quickly the company can unlock value from the asset.

Summarised by Beize from a story on The Economic Times on 24 Apr 2026

Reading on mobile?

App StorePlay Store
Government boosts pharma feedstock supplies to shield medicine prices from West Asia shocks

Government boosts pharma feedstock supplies to shield medicine prices from West Asia shocks

India is increasing petrochemical feedstock supplies to pharmaceutical manufacturers to protect essential medicine availability amid West Asia supply-chain disruptions. Refiners are now pushing key inputs such as propylene, ammonia and methanol, while customs duties have been reduced to lower landed costs. As a result, domestic drug prices are holding steady.

Summarised by Beize from a story on The Economic Times on 24 Apr 2026
India obesity drug market set to surge as oral GLP1 pills replace injections for millions

India obesity drug market set to surge as oral GLP1 pills replace injections for millions

India’s obesity treatment market is expected to change quickly by year-end as oral GLP1 weight-loss pills become widely available, including new options from China. These tablet therapies promise a cheaper, easier alternative to injectable GLP1 drugs, which could boost patient adoption as convenience and affordability rise. Market analysts expect demand to accelerate as more people can access treatment.

Summarised by Beize from a story on The Economic Times on 24 Apr 2026
Trump pharma tariff push hits branded drugs but exemptions shrink the damage

Trump pharma tariff push hits branded drugs but exemptions shrink the damage

The US has moved to impose tariffs on branded drug imports, aiming to spur domestic manufacturing. But the impact may be limited because key exemptions cover companies investing in US production and imports from countries with trade agreements. Generics are unaffected, leaving Indian exporters of branded medicines needing to reassess the new compliance and pricing rules.

Summarised by Beize from a story on The Economic Times on 24 Apr 2026
Alembic Pharma wins USFDA nod for generic methotrexate injection for cancer and arthritis

Alembic Pharma wins USFDA nod for generic methotrexate injection for cancer and arthritis

Alembic Pharmaceuticals has received USFDA final approval for its generic methotrexate injection, a widely used medicine for multiple cancers and inflammatory conditions. The regulator greenlit key dosage formats and confirmed therapeutic equivalence to the reference Hospira product, clearing the way for Alembic to market the injectable in the US for cancers and conditions like rheumatoid arthritis and severe psoriasis.

Summarised by Beize from a story on The Economic Times on 24 Apr 2026

Follow your favourite sources

App StorePlay Store
Paracetamol price shock looms as Vizag chemists warn 40 percent cost surge risk

Paracetamol price shock looms as Vizag chemists warn 40 percent cost surge risk

A war-linked pharma cost shock is now rippling into India’s healthcare market. Vizag chemists say paracetamol and other essential generics may see hikes of 30–40% as manufacturers face surging raw material prices, especially from West Asia. Current supplies are said to be stable, but future revisions could raise retail bills. The government is working to curb volatility and maintain availability.

Summarised by Beize from a story on The Economic Times on 24 Apr 2026
Alkem Labs CEO Vikas Gupta likely to step down amid upcoming leadership change

Alkem Labs CEO Vikas Gupta likely to step down amid upcoming leadership change

Alkem Labs, an Indian drug maker, is preparing for a top management shift. CEO Vikas Gupta, who has led the company for nearly three years, is expected to leave in the coming months. Gupta previously worked at Cipla before joining Alkem and brings deep experience in India’s pharmaceutical market. The company has not detailed a successor yet.

Summarised by Beize from a story on The Economic Times on 24 Apr 2026
Drug makers hit blockbuster jackpots by resurrecting once dumped pipeline compounds

Drug makers hit blockbuster jackpots by resurrecting once dumped pipeline compounds

Recent blockbuster wins suggest global drug makers aren’t just succeeding through long-term research. Companies have repeatedly found success by bringing pipeline compounds back from the discard pile, turning old bets into major drugs and vaccines. While strategy still matters, the pattern points to luck playing an outsized role in which therapies finally reach patients.

Summarised by Beize from a story on The Economic Times on 24 Apr 2026
Mankind eyes BSV after a 3x valuation surge in women’s health pharma turnaround

Mankind eyes BSV after a 3x valuation surge in women’s health pharma turnaround

A low-profile pharma firm, Advent controlled-BSV, has drawn major investor attention after a turnaround that tripled its valuation in five years. Its focus on specialised women’s health products and a strong research pipeline have helped drive the momentum. Now, Mankind is set to acquire BSV in a $1.6 billion deal, putting the company’s next growth phase in the spotlight.

Summarised by Beize from a story on The Economic Times on 24 Apr 2026

Stay informed on the go

App StorePlay Store
Sun Pharma bids $13 billion for Organon to leap into global branded drugs

Sun Pharma bids $13 billion for Organon to leap into global branded drugs

Sun Pharmaceutical has made a bold $13 billion bid for US firm Organon & Co., signaling its biggest push to shift from generics toward branded and innovative medicines. Sun is competing with other bidders for Organon, and a successful deal would effectively merge Organon into Sun Pharma, reshaping its global ambitions.

Summarised by Beize from a story on The Economic Times on 24 Apr 2026
Novo Nordisk eases insulin plan leaving a major opening for Eris and Biocon Biologics

Novo Nordisk eases insulin plan leaving a major opening for Eris and Biocon Biologics

Novo Nordisk’s partial phase out of a key insulin product in India may create a supply gap that competitors are ready to fill. Eris Pharma and its contract manufacturing partner Biocon Biologics could benefit as demand shifts and procurement patterns adjust. The move could trigger pricing and market share changes across India’s insulin landscape, with near-term opportunities for local players.

Summarised by Beize from a story on The Economic Times on 24 Apr 2026
Page 1

The full experience is on mobile.

Swipe through stories, personalise your feed, and save articles for later — all on the app.

Download on the App StoreGet it on Google Play